Shots:

• The P-IIb PAGANINI study involves assessing the efficacy- safety & tolerability of eliapixant (25- 75 or 150mg- bid) vs PBO in 310 patients with RCC for 12wks. and it lasted for 18wks. in total
• The study met its 1EPs i.e. reduction in the 24hrs. cough count of up to 27% with 75mg dose and showed a positive benefit-risk profile with mild to moderate AEs. The results of the PAGANINI study were presented at the virtual ERS International Congress 2021
• Eliapixant (BAY1817080- PO) is an investigational potent and selective P2X3 receptor antagonist

  | Ref: Bayer | Image: Bayer